JP2013505268A - 癌の治療におけるsparc微小環境シグネチャの使用 - Google Patents

癌の治療におけるsparc微小環境シグネチャの使用 Download PDF

Info

Publication number
JP2013505268A
JP2013505268A JP2012529971A JP2012529971A JP2013505268A JP 2013505268 A JP2013505268 A JP 2013505268A JP 2012529971 A JP2012529971 A JP 2012529971A JP 2012529971 A JP2012529971 A JP 2012529971A JP 2013505268 A JP2013505268 A JP 2013505268A
Authority
JP
Japan
Prior art keywords
tumor
sparc
antibody
sms
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012529971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505268A5 (cg-RX-API-DMAC7.html
Inventor
チェウ、ヴォン
デサイ、ニール
Original Assignee
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー filed Critical アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー
Publication of JP2013505268A publication Critical patent/JP2013505268A/ja
Publication of JP2013505268A5 publication Critical patent/JP2013505268A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2012529971A 2009-09-18 2010-09-20 癌の治療におけるsparc微小環境シグネチャの使用 Pending JP2013505268A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27696909P 2009-09-18 2009-09-18
US61/276,969 2009-09-18
PCT/US2010/049545 WO2011035274A1 (en) 2009-09-18 2010-09-20 Use of the sparc microenvironment signature in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2013505268A true JP2013505268A (ja) 2013-02-14
JP2013505268A5 JP2013505268A5 (cg-RX-API-DMAC7.html) 2013-11-07

Family

ID=43759058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012529971A Pending JP2013505268A (ja) 2009-09-18 2010-09-20 癌の治療におけるsparc微小環境シグネチャの使用

Country Status (13)

Country Link
US (1) US20120245089A1 (cg-RX-API-DMAC7.html)
EP (1) EP2478362B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013505268A (cg-RX-API-DMAC7.html)
KR (1) KR20120092597A (cg-RX-API-DMAC7.html)
CN (1) CN102576016A (cg-RX-API-DMAC7.html)
AU (1) AU2010295324B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012008316A2 (cg-RX-API-DMAC7.html)
CA (1) CA2774550A1 (cg-RX-API-DMAC7.html)
IL (1) IL218642A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012003287A (cg-RX-API-DMAC7.html)
NZ (1) NZ598801A (cg-RX-API-DMAC7.html)
WO (1) WO2011035274A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202657B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528337A (ja) * 2009-05-28 2012-11-12 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー 化学療法への反応を予測するための2つの抗sparc抗体の使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011261240A1 (en) * 2010-06-03 2013-01-10 Abraxis Bioscience, Llc Use of the SPARC microenvironment signature in the treatment of cancer
EP3539080B1 (en) * 2016-11-10 2022-03-23 F. Hoffmann-La Roche AG Distance-based tumor classification

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008060651A2 (en) * 2006-03-31 2008-05-22 Abraxis Bioscience, Inc. Sparc and methods of use thereof
WO2008076373A1 (en) * 2006-12-14 2008-06-26 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
JP2008530248A (ja) * 2005-02-18 2008-08-07 アブラクシス バイオサイエンス, インコーポレイテッド 治療薬の組み合わせおよび投与の様式ならびに併用療法
WO2008128169A1 (en) * 2007-04-13 2008-10-23 Abraxis Bioscience, Inc. Sparc and methods of use thereof
WO2008150532A1 (en) * 2007-06-01 2008-12-11 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5003621A (en) 1989-11-02 1991-03-26 Motorola, Inc. Direct conversion FM receiver
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO2004085621A2 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
ATE511550T1 (de) * 2003-07-17 2011-06-15 Pacific Edge Biotechnology Ltd Marker zum nachweis von magenkrebs
JP4682152B2 (ja) * 2003-12-31 2011-05-11 ザ・ペン・ステート・リサーチ・ファンデーション 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
GB0417740D0 (en) * 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
AU2005297303B2 (en) * 2004-10-19 2011-11-10 Lsip, Llc Novel diagnostic kit for malignant melanoma
WO2006112930A2 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
RU2451521C2 (ru) * 2006-06-16 2012-05-27 Онкотерапи Сайенс, Инк. Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их
AU2008226283A1 (en) * 2007-03-09 2008-09-18 The University Of British Columbia Assessing chemotherapy resistance of colorectal tumors by determining sparc hypermethylation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008530248A (ja) * 2005-02-18 2008-08-07 アブラクシス バイオサイエンス, インコーポレイテッド 治療薬の組み合わせおよび投与の様式ならびに併用療法
WO2008060651A2 (en) * 2006-03-31 2008-05-22 Abraxis Bioscience, Inc. Sparc and methods of use thereof
WO2008076373A1 (en) * 2006-12-14 2008-06-26 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
WO2008128169A1 (en) * 2007-04-13 2008-10-23 Abraxis Bioscience, Inc. Sparc and methods of use thereof
WO2008150532A1 (en) * 2007-06-01 2008-12-11 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUMAN PATHOLOGY, vol. 30, JPN6014042342, 1999, pages 339 - 344, ISSN: 0002913963 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 25, JPN6014042343, 2007, pages 319 - 325, ISSN: 0002913964 *
LABORATORY INVESTIGATION, vol. 88, JPN6014042340, 2008, pages 591 - 601, ISSN: 0002913961 *
PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, vol. 72, JPN6014042341, 2005, pages 267 - 272, ISSN: 0002913962 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528337A (ja) * 2009-05-28 2012-11-12 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー 化学療法への反応を予測するための2つの抗sparc抗体の使用

Also Published As

Publication number Publication date
AU2010295324A1 (en) 2012-04-05
US20120245089A1 (en) 2012-09-27
BR112012008316A2 (pt) 2017-06-06
WO2011035274A1 (en) 2011-03-24
CN102576016A (zh) 2012-07-11
IL218642A0 (en) 2012-05-31
AU2010295324B2 (en) 2015-04-30
MX2012003287A (es) 2012-08-03
EP2478362B1 (en) 2016-05-11
ZA201202657B (en) 2013-09-25
EP2478362A1 (en) 2012-07-25
NZ598801A (en) 2014-07-25
CA2774550A1 (en) 2011-03-24
EP2478362A4 (en) 2013-09-11
KR20120092597A (ko) 2012-08-21

Similar Documents

Publication Publication Date Title
US20130281376A1 (en) Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer
CN101454673A (zh) Sparc及其使用方法
US9193782B2 (en) Use of the SPARC microenvironment signature in the treatment of cancer
US9091697B2 (en) Use of 2 anti-SPARC antibodies to predict response to chemotherapy for pancreatic adenocarcinoma
US20140005059A1 (en) Biomarkers for cancer
AU2010295324B2 (en) Use of the SPARC microenvironment signature in the treatment of cancer
HK1172689A (en) Use of the sparc microenvironment signature in teh treatment of cancer
HK1170809B (en) Use of 2 anti-sparc antibodies to predict response to chemotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150721